|
|
 |
|
Viewing report
|
|
|
|
European In-Vitro Cancer Diagnostics Markets
Frost & Sullivan, June 2000
This report from Frost & Sullivan divides the in-vitro cancer diagnostics market into an in-depth analysis in each of the four segments - immunoassay, immuno-histochemistry, clinical chemistry and nucleic acid based. This report focuses specifically upon the markets in Germany, France, Italy, United Kingdom, Spain, Benelux, and Scandinavia. New technologies are emerging in the field of in-vitro cancer diagnostics. Tools that are used to diagnose, screen and monitor specific types of cancer may have a profound effect upon this industry. Nucleic acid base testing, based on polimerase chain reaction (PCR), and fluorescent in-situ hybridization (FISH) technologies are set to revolutionize the cancer diagnostic market by providing much of the revenue growth in the medium and long term. These novel techniques offer a higher level of specificity and sensitivity than traditional technologies, enabling earlier detection of cancer and enhanced follow-up testing. The launch of new chemosensitive assays, which establish whether or not patients are genetically compatible with cancer therapies, will create a new market in the field of in-vitro cancer diagnostic testing, states the author of the report.
The European in-vitro cancer diagnostics market has recently experienced declining revenues as a result of the consolidation of testing laboratories. This consolidation enhanced end-user purchasing power, leading to falling prices in the immunoassay and clinical chemistry markets, which deterred many new entrants from joining the market. Ten companies in this market now hold eighty-three percent of the market share. In light of this consolidation trend, small and medium-sized companies have been struggling to maintain the adequate level of research and development, spending what is necessary to continue to provide a broad range of testing parameters. Smaller firms are finding they must concentrate on niche marketing areas in order to avoid being forced out of the market altogether. However, opportunities still exist in this market because of the rising patient population and the development of new genetic markers. In addition, DNA amplification and FISH technologies provide new opportunities for companies to develop new, highly sensitive and specific testing parameters. This Frost & Sullivan report helps users keep a close watch on the competitive environment of the in-vitro cancer diagnostics markets, and offers the solutions needed to pull ahead of the competition.
Customers who bought this item also bought
Immunoassay Systems - Global Strategic Business Report
European Nucleic Acid-based Amplification Reagents Markets for Clinical Applications
Molecular Diagnostics - Technologies, Markets and Companies
Point of Care Testing: Evaluating the Return to Evidence Based Medicine, Novel Technologies and the Competitive Landscape
Molecular Diagnostics - Global Strategic Business Report
The 2011 Therapeutic Drug Monitoring Market: US, Europe, Japan - Test Volume and Sales Forecasts by Country and Market Segment
Future Japanese Clinical Chemistry and Immunodiagnostics Markets: Growth Opportunities and Business Expansion Strategies
In Vitro Diagnostics Market in the US
In-vitro Diagnostics Market Outlook in Australia
Future Clinical Chemistry and Immunodiagnostics Markets: Growth Opportunities and Business Expansion Strategies
|
|
|
|
